
Oral Proteins and Peptides Market Report and Forecast 2025-2034
Description
The global oral proteins and peptides market size was valued at USD 2.50 Billion in 2024, driven by the growing biotechnological and pharmaceutical advancements across the globe. The market is expected to grow at a CAGR of 14.50% during the forecast period of 2025-2034, with the value likely to rise to USD 9.68 Billion by 2034.
Global Oral Proteins and Peptides Market Overview
Oral proteins and peptides involve the administration of large biomolecules orally, usually in the form of capsules, pills, or liquid formulations. Oral delivery is commonly preferred over the intravenous methods as it offers a patient friendly and painless option. The non-invasive nature of oral route of drug administration leads to improved quality of life, especially for those requiring long-term or chronic treatment. It may also facilitate fewer visits to the healthcare facilities and a minimized risk of infection. Such factors have led to increased oral proteins and peptides market demand in recent years.
Increasing Burden of Chronic Diseases to be the Key Growth Driver
Oral insulin is a key area of research owing to the rising prevalence of diabetes. Currently, approximately half a billion people are living with diabetes worldwide and the incidence is expected to rise to double and reach 1.3 billion in the next 30 years . Therefore, oral proteins and peptides can be considered as a convenient way to offer improved and effective solutions for the patients suffering from the disease. They are also being investigated to treat other conditions such as osteoporosis, cancer, inflammatory bowel disease, and autoimmune diseases and the growing prevalence of such diseases is anticipated to boost the oral peptides and proteins market growth in the forecast period.
Surge in Technical Advancements to Develop New Drugs
With increasing advancements in biotechnology as well as gene technology, designing oral peptides has also become comparatively easier. Researchers can now combat the constraints of oral peptide and protein delivery systems which include unfavourable physicochemical properties such as large molecular size, along with the tendency to undergo enzymatic degradation, aggregation, adsorption, and denaturation. Such technical innovations are expected to boost the oral proteins and peptides market size. In January 2023, the scholars at Uppsala University constructed a new machine for protein separation. The new method helps in capillary electrophoresis (which helps in molecular segregation based on different charges) in a cost-effective manner.
Expediated Drug Development to Address Multiple Diseases
In November 2023, Entera Bio Ltd., an oral peptide company, revealed development on five new oral peptides programs. There is development on the first Osteoporosis oral and osteoanabolic drug, called EB613. The company partnered with the American Society for Bone and Mineral Research (ASBMR) to submit the drug for FDA approval. The oral proteins and peptide market share is anticipated to grow with increased number of drugs under pipeline for multiple diseases. EB613 for intense sports and military stress injuries, EB612 for hypoparathyroidism, GLP-2 peptide tablets for short bowel syndrome, and GLP-1 peptides for obesity are some of the prominent examples of drugs under a pipeline.
Development of New Devices to Facilitate Oral Route of Administration
In September 2023, Biora Therapeutics, Inc., revealed their company’s latest invention, a BioJet™ platform for oral and systemic delivery of biotherapeutics. The platform uses an ingestible capsule, approximately like the size of a multivitamin and designed to transit through the digestive system and get activated in the small intestine. It can be used to deliver a wide of molecules including proteins, nucleic acids, and peptides in liquid formulations up to 400µL. It is an effective needle free route of delivering large molecules and is expected to replace injections for better management of chronic diseases.
Global Oral Proteins and Peptides Market Segmentation
Oral Proteins and Peptides Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
North America, led by the United States and Canada, is expected to lead the oral proteins and peptides market share in the forecast period. The market size can be accredited to a robust biotech along with research and development infrastructure. The existence of proactive regulatory authorities like the FDA also ensures the drug efficacy and contributes to the growth of the market.
With the presence of key academic institutions and pharmaceutical companies, Europe is another major market for oral proteins and peptides. The rising partnerships between the public and private entities is also garnering developments in the drug markets. The high prevalence of diseases such as diabetes and other bone related issues in the geriatric population also pushes innovation for improved patient alternatives.
Asia Pacific is expected to witness the oral proteins and peptides market growth attributed to rising investment in improving the research and development infrastructure. Moreover, the increasing influx of foreign capital is a major aspect of the market growth.
Global Oral Proteins and Peptides Market: Competitor Landscape
In September 2023, Entera Bio Ltd. partnered with OPKO Health, Inc., under a research agreement to expand their oral delivery technology across two extra peptides, namely GLP-2 for the treatment of short bowel syndrome, and Oxyntomodulin (OXM), a dual targeted GLP-1/glucagon agonist for treating obesity. Under the terms of the agreement, the companies will be responsible for specific phases of development leveraging their area of expertise.
The key features of the oral proteins and peptides market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Global Oral Proteins and Peptides Market Overview
Oral proteins and peptides involve the administration of large biomolecules orally, usually in the form of capsules, pills, or liquid formulations. Oral delivery is commonly preferred over the intravenous methods as it offers a patient friendly and painless option. The non-invasive nature of oral route of drug administration leads to improved quality of life, especially for those requiring long-term or chronic treatment. It may also facilitate fewer visits to the healthcare facilities and a minimized risk of infection. Such factors have led to increased oral proteins and peptides market demand in recent years.
Increasing Burden of Chronic Diseases to be the Key Growth Driver
Oral insulin is a key area of research owing to the rising prevalence of diabetes. Currently, approximately half a billion people are living with diabetes worldwide and the incidence is expected to rise to double and reach 1.3 billion in the next 30 years . Therefore, oral proteins and peptides can be considered as a convenient way to offer improved and effective solutions for the patients suffering from the disease. They are also being investigated to treat other conditions such as osteoporosis, cancer, inflammatory bowel disease, and autoimmune diseases and the growing prevalence of such diseases is anticipated to boost the oral peptides and proteins market growth in the forecast period.
Surge in Technical Advancements to Develop New Drugs
With increasing advancements in biotechnology as well as gene technology, designing oral peptides has also become comparatively easier. Researchers can now combat the constraints of oral peptide and protein delivery systems which include unfavourable physicochemical properties such as large molecular size, along with the tendency to undergo enzymatic degradation, aggregation, adsorption, and denaturation. Such technical innovations are expected to boost the oral proteins and peptides market size. In January 2023, the scholars at Uppsala University constructed a new machine for protein separation. The new method helps in capillary electrophoresis (which helps in molecular segregation based on different charges) in a cost-effective manner.
Expediated Drug Development to Address Multiple Diseases
In November 2023, Entera Bio Ltd., an oral peptide company, revealed development on five new oral peptides programs. There is development on the first Osteoporosis oral and osteoanabolic drug, called EB613. The company partnered with the American Society for Bone and Mineral Research (ASBMR) to submit the drug for FDA approval. The oral proteins and peptide market share is anticipated to grow with increased number of drugs under pipeline for multiple diseases. EB613 for intense sports and military stress injuries, EB612 for hypoparathyroidism, GLP-2 peptide tablets for short bowel syndrome, and GLP-1 peptides for obesity are some of the prominent examples of drugs under a pipeline.
Development of New Devices to Facilitate Oral Route of Administration
In September 2023, Biora Therapeutics, Inc., revealed their company’s latest invention, a BioJet™ platform for oral and systemic delivery of biotherapeutics. The platform uses an ingestible capsule, approximately like the size of a multivitamin and designed to transit through the digestive system and get activated in the small intestine. It can be used to deliver a wide of molecules including proteins, nucleic acids, and peptides in liquid formulations up to 400µL. It is an effective needle free route of delivering large molecules and is expected to replace injections for better management of chronic diseases.
Global Oral Proteins and Peptides Market Segmentation
Oral Proteins and Peptides Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
- Plecanatide
- Linaclotide
- Octreotide
- Calcitonin
- Insulin
- Gastric and Digestive Disorders
- Bone Diseases
- Diabetes
- Hormonal Disorders
- Hospitals
- Ambulatory Surgical Centre
- Clinics
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
North America, led by the United States and Canada, is expected to lead the oral proteins and peptides market share in the forecast period. The market size can be accredited to a robust biotech along with research and development infrastructure. The existence of proactive regulatory authorities like the FDA also ensures the drug efficacy and contributes to the growth of the market.
With the presence of key academic institutions and pharmaceutical companies, Europe is another major market for oral proteins and peptides. The rising partnerships between the public and private entities is also garnering developments in the drug markets. The high prevalence of diseases such as diabetes and other bone related issues in the geriatric population also pushes innovation for improved patient alternatives.
Asia Pacific is expected to witness the oral proteins and peptides market growth attributed to rising investment in improving the research and development infrastructure. Moreover, the increasing influx of foreign capital is a major aspect of the market growth.
Global Oral Proteins and Peptides Market: Competitor Landscape
In September 2023, Entera Bio Ltd. partnered with OPKO Health, Inc., under a research agreement to expand their oral delivery technology across two extra peptides, namely GLP-2 for the treatment of short bowel syndrome, and Oxyntomodulin (OXM), a dual targeted GLP-1/glucagon agonist for treating obesity. Under the terms of the agreement, the companies will be responsible for specific phases of development leveraging their area of expertise.
The key features of the oral proteins and peptides market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novo Nordisk A/S
- Synergy Pharmaceuticals Inc.
- Chiasma Inc.
- Tarsa Therapeutics Inc.
- Biocon Limited
- Generex Biotechnology Corp.
- AstraZeneca PLC
- Proxima Concepts Limited
- Oramed Pharmaceuticals Inc.
- Allergan Plc.
- Generex Biotechnology Corp.
- Hoffmann-La Roche
- Sanofi
- Bristol-Myers Squibb Company
- Hovione
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Oral Proteins and Peptides Market Overview
- 3.1 Global Oral Proteins and Peptides Market Historical Value (2018-2024)
- 3.2 Global Oral Proteins and Peptides Market Forecast Value (2025-2034)
- 4 Global Oral Proteins and Peptides Market Landscape
- 4.1 Global Oral Proteins and Peptides Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Oral Proteins and Peptides Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Products
- 5 Global Oral Proteins and Peptides Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Oral Proteins and Peptides Market Segmentation
- 6.1 Global Oral Proteins and Peptides Market by Drug Type
- 6.1.1 Market Overview
- 6.1.2 Plecanatide
- 6.1.3 Linaclotide
- 6.1.4 Octreotide
- 6.1.5 Calcitonin
- 6.1.6 Insulin
- 6.2 Global Oral Proteins and Peptides Market by Application
- 6.2.1 Market Overview
- 6.2.2 Gastric and Digestive Disorders
- 6.2.3 Bone Diseases
- 6.2.4 Diabetes
- 6.2.5 Hormonal Disorders
- 6.3 Global Oral Proteins and Peptides Market by End User
- 6.3.1 Market Overview
- 6.3.2 Hospitals
- 6.3.3 Ambulatory Surgical Centre
- 6.3.4 Clinics
- 6.4 Global Oral Proteins and Peptides Market by Region
- 6.4.1 Market Overview
- 6.4.2 North America
- 6.4.3 Europe
- 6.4.4 Asia Pacific
- 6.4.5 Latin America
- 6.4.6 Middle East and Africa
- 7 North America Oral Proteins and Peptides Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Oral Proteins and Peptides Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Oral Proteins and Peptides Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Others
- 10 Latin America Oral Proteins and Peptides Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Oral Proteins and Peptides Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
- 14.1 Analysis by Trial Registration Year
- 14.2 Analysis by Trial Status
- 14.3 Analysis by Trial Phase
- 14.4 Analysis by Therapeutic Area
- 14.5 Analysis by Geography
- 15 Funding Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Novo Nordisk A/S
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisition
- 17.1.5 Certifications
- 17.2 Synergy Pharmaceuticals Inc.
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisition
- 17.2.5 Certifications
- 17.3 Chiasma Inc.
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisition
- 17.3.5 Certifications
- 17.4 Tarsa Therapeutics Inc.
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisition
- 17.4.5 Certifications
- 17.5 Biocon Limited
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisition
- 17.5.5 Certifications
- 17.6 Generex Biotechnology Corp.
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisition
- 17.6.5 Certifications
- 17.7 AstraZeneca PLC
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisition
- 17.7.5 Certifications
- 17.8 Proxima Concepts Limited
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisition
- 17.8.5 Certifications
- 17.9 Oramed Pharmaceuticals Inc.
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisition
- 17.9.5 Certifications
- 17.10 Allergan Plc.
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisition
- 17.10.5 Certifications
- 17.11 Generex Biotechnology Corp.
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisition
- 17.11.5 Certifications
- 17.12 Hoffmann-La Roche
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisition
- 17.12.5 Certifications
- 17.13 Sanofi
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisition
- 17.13.5 Certifications
- 17.14 Bristol-Myers Squibb Company
- 17.14.1 Financial Analysis
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisition
- 17.14.5 Certifications
- 17.15 Hovione
- 17.15.1 Financial Analysis
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisition
- 17.15.5 Certifications
- 18 Global Oral Proteins and Peptides Market - Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.